Last reviewed · How we verify

NCT06372990: BDTc

Rapid T-cell Analysis Test in Patients With Chronic HBV and HBV/HDV Disease

Recruiting now Last updated 15 January 2026
What this trial tests

trial in HBV in 300 participants. Currently enrolling.

Timeline
15 April 2024
Primary endpoint
30 September 2025
30 September 2026

Quick facts

Lead sponsorFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment300
Start date15 April 2024
Primary completion30 September 2025
Estimated completion30 September 2026
Sites1 location across Italy

Conditions studied

Sponsor

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Who can join

18 and older, any sex, with HBV or HBV/HDV. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective, non-pharmacological, single-center, non-profit observational study. The study design allows longitudinal evaluation of the immune response during the natural history of the infection and/or treatment, correlating the data with the outcome of the disease and antiviral therapies, which will be collected as study variables from the source documents. The study population will be patients suffering from chronic HBV infection with or without HBV-HDV co-infection followed at the Division of Gastroenterology and Hepatology of Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico. The present study is part of an international cooperation project between the Division of Gastroenterology and Hepatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (Milan, Italy) and the Duke-NUS Medical School, Singapore, financed by a grant (project MAECI-2023-23683653) and divided into two specific Work Packages: * WP 1 Milan team (WP1.1 - Clinical and virological phenotyping of CHB and CHD patients; WP1.2 - Clinical evaluation of rapid HBV T cell test in CHB and CHD populations) * WP 2 Singapore team (WP2.1 - Applicability of the rapid T cell assay approach; WP 2.2 - Optimization of the rapid T cell assay protocol) The primary objective of the study is to define the prevalence of specific T cell responses in patients with chronic HBV and HBV-HDV infection, through the application of a specific rapid T cell assay.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for HBV

Currently open trials in the same condition.

Other Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06372990.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing